Roivant Sciences: $1.4 Billion in Insider Sales — All Four Exit to Zero Shares
Four Roivant Sciences insiders have generated $1.41 billion in combined sales. Hedge fund manager Daniel Gold ($619M), QVT Financial ($578M), Keith Manchester ($170M), and President Sukhatme ($45M) all hold zero shares.
Four insiders at Roivant Sciences (ROIV) have sold a combined $1.41 billion in stock — and every single one of them now holds zero shares. The biotech-focused "vant" platform company has seen its most prominent backers completely exit.
Daniel Gold: The $619 Million Exit
Hedge fund manager Daniel Allen Gold leads the group with a staggering $619.4 million in career sales across 228 transactions. His recent selling wave of $149.8 million brought his holdings to zero. Gold, who manages QVT Financial, was one of Roivant's earliest and largest backers — and has now fully monetized that bet.
QVT Financial: $578 Million
QVT Financial LP, Gold's investment vehicle, separately recorded $578.5 million in sales across 209 transactions. The recent $126.9 million in sales completed the fund's exit. Between Gold's personal account and QVT, the combined exit exceeds $1.19 billion from a single investment thesis.
The Complete Exit
| Insider / Entity | Career Sales | Transactions | Recent Sales | Shares After |
|---|---|---|---|---|
| Daniel Allen Gold | $619.4M | 228 | $149.8M | 0 |
| QVT Financial LP | $578.5M | 209 | $126.9M | 0 |
| Keith S. Manchester | $169.6M | 57 | $103.9M | 0 |
| Mayukh Sukhatme | $45.1M | 43 | $45.1M | 0 |
Keith Manchester: $170 Million
Keith S. Manchester has sold $169.6 million across 57 transactions, with a massive $103.9 million in recent sales clearing his entire position. Manchester has been deeply involved with Roivant's "vant" model — the strategy of launching multiple subsidiary biotech companies under a shared platform.
President Exits With $45 Million
President and CIO Mayukh Sukhatme rounds out the quartet with $45.1 million in career sales across 43 transactions — notably, all of it in recent sales, suggesting a rapid, concentrated exit rather than gradual diversification. Like the others, Sukhatme holds zero shares.
What $1.4 Billion in Exits Means
Roivant's market cap is approximately $10 billion. The $1.41 billion in insider sales represents roughly 14% of the company's entire current value being extracted by just four insiders. With the company's highest-conviction backers completely exited, the ownership structure has fundamentally shifted.
The Roivant model — incubating subsidiary biotechs like Dermavant, Immunovant, and Proteovant — requires long-term capital commitment. The complete exit of its most prominent insiders raises questions about whether the remaining portfolio of "vants" justifies current valuations.
View all Roivant insider activity at ROIV stock page.
Related Research
Explore all researchAssenagon's 2026Q1 13F showed a $65.87B reported portfolio with Microsoft, Amazon, Apple and Nvidia together carrying a large top-four weight.
INTC has 2,592 tracked institutional holders. This research separates passive scale from active sponsorship.
GOOGL has 5,829 tracked institutional holders. This research separates passive scale from active sponsorship.
KEYBANK NATIONAL ASSOCIATION/OH reported 27.38B in 2026Q1 13F assets. The filing is most useful as a holder-depth and concentration map, not a raw clone list.
Retirement Systems of Alabama reported 29.98B in 2026Q1 13F assets. The filing is most useful as a holder-depth and concentration map, not a raw clone list.